Physician profile
Mohammad Elbashabsheh
NPI 1619461894
$999.21
in general payments reported to CMS, 2019-2025
10 companies · $40.78 in 2025
The $40.78 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $148 · 2022: $116 · 2023: $338 · 2024: $232 · 2025: $40.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $185.68 | 2023-2025 | |
| Viiv Healthcare Company | $145.20 | 2024 | Apretude |
| Astrazeneca Pharmaceuticals Lp | $124.92 | 2019 | |
| Insmed, INC. | $120.33 | 2023 | Arikayce |
| Janssen Pharmaceuticals, INC | $117.62 | 2020 | |
| Shionogi INC | $116.11 | 2022 | |
| Abbvie INC. | $108.84 | 2023-2024 | |
| Astellas Pharma US INC | $29.99 | 2020 | |
| Aimmune Therapeutics, INC. | $27.40 | 2023-2024 | |
| Cipher Pharmaceuticals US LLC | $23.12 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Elbashabsheh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.